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Letters to Editor
'Tumour volume'
Sir
We were interested to read the paper on survival after resection
of non-small-cell lung cancer (NSCLC) in relation to 'tumour
volume' by Jefferson et al (1996).
By multiplying together the three dimensions of each tumour,
the authors have assumed that the carcinomas are box shaped. The
accuracy of this assumption was not validated. In a study of 54
resected lung cancers (Binks et al, 1996), we found that the most
appropriate measures of tumour volume were to assume that the
tumours were ellipsoidal orboxes. These measurements compared
well with our gold standard methods (R = 0.887 and R = 0.910
respectively) of sequential 1-mm or 1-cm slices, for which the
tumour area was measured and the volume derived from the sum
ofthe areas. In contrast, measurement ofthe maximum dimension
and assuming a spherical shape grossly overestimated the volume
of some tumours (R = 0.632).
Although we expected ellipsoidal measurements to be more
accurate than boxes, this was not the case. We support the authors
statement that tumour volume is a useful piece of information that
is easily collected, but three dimensions should always be
measured for solid tumours.
Yours faithfully
CA Clelland, Nottingham City Hospital, NHS TrustHucknall
Road, Nottingham, NG5 JPB UK
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High-dose 5-fluorouracil infusional therapy is associated
with hyperammonaemia, lactic acidosis and
encephalopathy
Sir
Keywords: high-dose 5-fluorouracil; encephalopathy
Recently, weekly 24-h infusion ofhigh-dose 5-fluorouracil (5-FU)
and folinic acid has become a popular regimen (Ardalan et al,
1991; Aranda et al, 1995; Leichman et al, 1995). Although unusu-
ally high doses, up to 2600 mg mi-2 per week of 5-FU and 500 mg
m-2 per week of folinic acid, were administered, the toxicities of
myelosuppression and mucositis were surprisingly low. In our
institution, chemotherapeutic protocols incorporating 24-h infu-
sion of high-dose 5-FU (2600 mg m-2 per week) and leucovorin
(300 mg m-2 per week) (HDFL) have been used in treatment of
various cancers, including colorectal cancer, gastric cancer, breast
cancer, urological cancer, and head and neck cancer (Yeh et al,
1994a). Our experience of the treatment-related toxicities of
HDFL has largely been in keeping with those reported by Ardalan
et al (1991),except an unusual encephalopathy which first came to
our attention in 1992 (Yeh et al, 1994b). Since then, we have
encountered a spectrum of encephalopathy, including disorienta-
tion, confusion, agitation, neurosensory hearing impairment,
seizure, stupor and deep coma, associated with the use of HDFL
regimens. This encephalopathy was unique in that its development
and severity were closely related to the emergence of hyperam-
monaemia and lactic acidosis. Thus, it should be distinguished
from other 5-FU-associated toxicities previously reported.
Among 280 patients who had received HDFL in our institution
between 1991 and 1995, 16 (5.7%) developed HDFL-related
encephalopathy. The diagnostic criteria included: (1) development
of encephalopathy during or shortly after completion of HDFL
administration; (2) exclusion of other metabolic or physical factors
that may have an effect on the consciousness level, such as hyper-
glycaemia, hypoglycaemia, azotaemia, hepatic failure, electrolyte
imbalance, sepsis and central nervous system involvement of
cancers; and (3) exclusion of a drug effect by concomitant medica-
tions. The incidence of this complication was highest in gastric
cancer (12.1%), followed by breast cancer (4.3%) and colorectal
cancer(2.4%). Thirteen (81.3%) of 16patients had severe symptoms
of stupor or coma; in two patients these symptoms were combined
with seizure. Severe (grade III-IV) nausea and vomiting and a
Kussmaul's respiration were noted in 15 (93.8%) and 16 (100%)
patients respectively during the attack of encephalopathy. The
median time ofonset ofencephalopathy was 195Jp (range 10-30 h
from the start of HDFL infusion, and the m an duration of
encephalopathy between discontinuation of HD1_Land complete
recovery was 15 h (range 3-72h). Allpatients recoveredcompletely,
except one who developed a bilateral neurosensory hearing impair-
ment that recovered partially. Electroencephalogram (EEG) exami-
nations of eight patients revealed diffuse cortical dysfunction with
diffuse slow waves or diffuse intermittent theta waves, suggesting
metabolic or toxic encephalopathy. Since our first experience ofthis
complication in 1992 (Yeh et al, 1994b), arterial blood gas, plasma
ammonia and plasma lactic acid were routinely examined in the
patients who had developed encephalopathy. Hyperammonaemia
(149 to >500 ,umol 1-', median 345) (reference level 19-43 ,umol 1-',
checked by ammonia-selective electrode), lactic acidosis (4.0 to> 12
mg dl-', median 9.2) (reference level 0.3-1.3 mg dl-') and hypo-
capnia (pCO2 15-30.1 mmHg, median 18.6) (reference level 35-45
mmHg) were found to parallel the development of encephalopathy.
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These abnormalities were not detected in patients who also received
HDFL treatment but did not develop encephalopathy (data not
shown). Further examination of a series of biochemical parameters
revealed thatthe serumtriglyceride level(43.2± 13.7 mgdl-') (refer-
ence level 50-130 mg dl-') ofthe 16patients was significantly lower
than that (126.4 ± 70.0 mg dl-') ofthe patients who did not develop
encephalopathy (P < 0.001 using Wilcoxon rank-sum test).
Although direct evidence is lacking, we have formulated a
hypothesis which appears to be the best fit for this scenario.
Ammonia is the 'end' product of 5-FU. Following high-dose 5-
FU administration, a large amount ofammonia is rapidly accumu-
lated and should normally be cleared by the ATP-dependent urea
cycle. In the case of HDFL treatment, a large amount of fluoroac-
etate, the 'intermediate' product of 5-FU, directly inhibits the
ATP-producing Kreb's cycle (Koenig et al, 1970; Mayes et al,
1993) and results in lactic acidosis and the impairment oftheATP-
dependent urea cycle. Hypotriglyceridaemia impairs the ATP-
producing lipolysis (5-oxidation) which should normally salvage
the ATP-deficiency state caused by an impaired Kreb's cycle. This
further jeopardizes the ATP-dependent urea cycle. The end result
is a transient hyperammonaemia state with encephalopathy.
It is necessary to consider differential diagnosis with other 5-
FU-related toxicities. Firstly, the familial deficiency of dihydropy-
rimidine dehydrogenase (DPD), the primary inactivating enzyme of
5-FU, should be ruled out. This situation usually results in severe
myelosuppression andgastrointestinal (GI)toxicity and may be asso-
ciated with a low level of catabolic products, including ammonia
(Tuchman etal, 1985; Diasio et al, 1988; Harris et al, 1991). The fact
that none ofourpatients haddeveloped significantmyelosuppression
or GI toxicities and that all ofthem had had hyperammonaemia did
not favour the possibility ofa DPD- deficiency state. A recent report
described a single patient with DPD deficiency who presented with
only mild GI and marrow toxicity (Takimoto et al, 1996). However,
comparing this case with the other 17 cases of classical DPD defi-
ciency reported in the literature (Tuchman et al, 1985; Diasio et al,
1988; Harris et al, 1991; Fleming et al, 1993; Houyau et al, 1993; Lu
et al, 1993; Lyss et al, 1993), we suggest that this patient might actu-
ally have developed a syndrome similar to that reported in this letter.
Secondly, high5-FU bloodconcentrations duetohepaticdysfunction
(Floyd et al, 1982) or DPD deficiency plus renal failure (Stephan et
al, 1995) should also be considered. It was apparent that none ofour
patients hadhepatic orrenal dysfunction. Finally,malnutrition andits
associated thiamine deficiency may contribute to this syndrome. 5-
FU exacerbates the pre-existing thiamine deficiency by blocking the
conversion ofthiamine to active thiamine pyrophosphate (Basu et al,
1974; Soukop et al, 1978). It should bepossible to reverse this condi-
tion using thiamine supplement (Aksoy et al, 1980). Thiamine
supplement had been tried with several of our patients; however,
none ofthem responded to this treatment (data not shown).
We suggest that (1) encephalopathy is an important complica-
tion ofHDFL treatment; (2) HDFL-related encephalopathy is asso-
ciated with unique biochemical changes of hyperammonaemia,
lactic acidosis and hypocapnia; and (3) patients with hypotriglyc-
eridaemia are relatively contraindicated for HDFL treatment.
Yours faithfully
KH Yeh, Department ofOncology, Taiwan University Hospital,
Cancer Research Center and Graduate Institute ofClinical
Medicine, National Taiwan University College ofMedicine,
Taipei, Taiwan, ROC
AL Cheng, Department ofOncology, Taiwan University Hospital,
Cancer Research Center andDepartment of
Internal Medicine, National Taiwan University Hospital, Taipei,
Taiwan, ROC
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